IRAK1 and T-cell acute lymphoblastic leukemia: In both melanoma and T cell acute lymphoblastic leukemia (T-ALL), a small-molecule IRAK1/4 inhibitor suppressed cell proliferation and enhanced chemotherapeutic responses [48, 49].